RU2650511C2 - Формы и составы пиримидинилциклопентанового соединения, композиции и способы, относящиеся к ним - Google Patents

Формы и составы пиримидинилциклопентанового соединения, композиции и способы, относящиеся к ним Download PDF

Info

Publication number
RU2650511C2
RU2650511C2 RU2014151016A RU2014151016A RU2650511C2 RU 2650511 C2 RU2650511 C2 RU 2650511C2 RU 2014151016 A RU2014151016 A RU 2014151016A RU 2014151016 A RU2014151016 A RU 2014151016A RU 2650511 C2 RU2650511 C2 RU 2650511C2
Authority
RU
Russia
Prior art keywords
methyl
piperazin
chlorophenyl
dihydro
isopropylamino
Prior art date
Application number
RU2014151016A
Other languages
English (en)
Russian (ru)
Other versions
RU2014151016A (ru
Inventor
Парома ЧАКРАВАРТИ
Санджив КОТХАРИ
Франсис ГОССЕЛЭН
Скотт Дж. Сэвидж
Джеффри СТАЛТС
Original Assignee
Дженентек, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=48539412&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2650511(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Дженентек, Инк. filed Critical Дженентек, Инк.
Publication of RU2014151016A publication Critical patent/RU2014151016A/ru
Application granted granted Critical
Publication of RU2650511C2 publication Critical patent/RU2650511C2/ru

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
RU2014151016A 2012-05-17 2013-05-17 Формы и составы пиримидинилциклопентанового соединения, композиции и способы, относящиеся к ним RU2650511C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261648536P 2012-05-17 2012-05-17
US61/648,536 2012-05-17
PCT/US2013/041728 WO2013173811A1 (en) 2012-05-17 2013-05-17 Amorphous form of an akt inhibiting pyrimidinyl - cyclopentane compound, compositions and methods thereof

Publications (2)

Publication Number Publication Date
RU2014151016A RU2014151016A (ru) 2016-07-10
RU2650511C2 true RU2650511C2 (ru) 2018-04-16

Family

ID=48539412

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2014151016A RU2650511C2 (ru) 2012-05-17 2013-05-17 Формы и составы пиримидинилциклопентанового соединения, композиции и способы, относящиеся к ним

Country Status (31)

Country Link
US (2) US9290458B2 (zh)
EP (2) EP2858989B9 (zh)
JP (2) JP6283663B2 (zh)
KR (4) KR20200074252A (zh)
CN (1) CN104470912B (zh)
AU (2) AU2013262548B2 (zh)
BR (1) BR112014028593A2 (zh)
CA (1) CA2873663C (zh)
CL (1) CL2014003115A1 (zh)
CO (1) CO7151489A2 (zh)
CR (1) CR20140560A (zh)
DK (1) DK2858989T3 (zh)
ES (1) ES2799512T3 (zh)
HK (1) HK1208462A1 (zh)
HR (1) HRP20200992T1 (zh)
HU (1) HUE051254T2 (zh)
IL (2) IL235712B (zh)
LT (1) LT2858989T (zh)
MA (1) MA37650A1 (zh)
MX (1) MX353041B (zh)
MY (1) MY170086A (zh)
NZ (1) NZ702513A (zh)
PE (1) PE20150725A1 (zh)
PH (1) PH12014502538A1 (zh)
PL (1) PL2858989T3 (zh)
PT (1) PT2858989T (zh)
RS (1) RS60417B9 (zh)
RU (1) RU2650511C2 (zh)
SG (1) SG11201407618VA (zh)
SI (1) SI2858989T1 (zh)
WO (1) WO2013173811A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104470913B (zh) 2012-05-17 2018-07-20 阵列生物制药公司 用于制造羟基化的环戊基嘧啶化合物的方法
PE20150725A1 (es) 2012-05-17 2015-05-17 Genentech Inc Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y metodos de este
EP4282973A3 (en) 2013-11-15 2024-03-27 F. Hoffmann-La Roche AG Processes for the preparation of pyrimidinylcyclopentane compounds
DK2946774T3 (da) 2014-05-19 2020-05-25 Tillotts Pharma Ag Coatede kapsler med modificeret frigivelse
JP6875501B2 (ja) * 2016-08-10 2021-05-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ａｋｔプロテインキナーゼ阻害剤を含む薬学的組成物
EP4013419A1 (en) * 2019-08-12 2022-06-22 F. Hoffmann-La Roche AG Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant
CA3221313A1 (en) * 2021-06-09 2022-12-15 Warren Miller Mixed solvents for spray drying for preparation of amorphous solid dispersions
WO2023043869A1 (en) 2021-09-15 2023-03-23 Teva Pharmaceuticals International Gmbh Solid state forms of ipatasertib citrate

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200601426A1 (ru) * 2004-02-11 2007-02-27 Эмджен Инк. Производные пиримидина для использования в качестве лигандов ваниллоидных рецепторов и их применение для терапии боли
WO2008006040A1 (en) * 2006-07-06 2008-01-10 Array Biopharma Inc. Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2178829A1 (en) 1993-12-12 1995-06-15 Yigal Cohen A novel method to protect plants from fungal infection
JP2001524079A (ja) 1997-04-07 2001-11-27 メルク エンド カンパニー インコーポレーテッド ガンの治療方法
US6201023B1 (en) 1997-06-10 2001-03-13 Agrogene Ltd. Methods and compositions to protect crops against plant parasitic nematodes
ES2137137B1 (es) 1998-05-25 2000-08-16 Medichem Sa Nuevo polimorfo de gabapentina no hidratada, su procedimiento de obtencion y su utilizacion para la obtencion de gabapentina de calidad farmaceutica.
EP0982300A3 (en) 1998-07-29 2000-03-08 Societe Civile Bioprojet Non-imidazole alkylamines as histamine H3 - receptor ligands and their therapeutic applications
US6376496B1 (en) 1999-03-03 2002-04-23 Merck & Co., Inc. Inhibitors of prenyl-protein transferase
AU7715300A (en) 1999-09-27 2001-04-30 Merck & Co., Inc. Method of preventing osteoporosis
BR0307333A (pt) 2002-02-01 2004-12-07 Pfizer Prod Inc Métodos para a preparação de dispersões homogéneas de fármacos sólidos amorfos atomizados utilizando um sistema de secagem por pulverização
JP4550811B2 (ja) 2003-06-09 2010-09-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング パピローマウイルスのインヒビター
EP1684694A2 (en) 2003-11-21 2006-08-02 Array Biopharma, Inc. Akt protein kinase inhibitors
US8927546B2 (en) 2006-02-28 2015-01-06 Dart Neuroscience (Cayman) Ltd. Therapeutic piperazines
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
CN101801955B (zh) 2007-07-05 2013-05-08 阵列生物制药公司 作为akt蛋白激酶抑制剂的嘧啶基环戊烷
WO2009047255A1 (en) 2007-10-09 2009-04-16 Ucb Pharma, S.A. Heterobicyclic compounds as histamine h4-receptor antagonists
AU2009204025B2 (en) * 2008-01-09 2014-02-20 Array Biopharma Inc. Hydroxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
EP2419404B1 (en) 2009-04-15 2015-11-04 AbbVie Inc. Anti-viral compounds
CA2778291C (en) 2009-10-23 2014-02-11 Eli Lilly And Company Akt inhibitors
CA2793892A1 (en) * 2010-04-16 2011-10-20 Elizabeth Punnoose Foxo3a as predictive biomarker for pi3k/akt kinase pathway inhibitor efficacy
US9050334B2 (en) 2010-07-16 2015-06-09 Innov88 Llc MIF inhibitors and their uses
WO2012177925A1 (en) 2011-06-21 2012-12-27 The Board Institute, Inc. Akt inhibitors for treating cancer expressing a magi3 - akt3 fusion gene
US9315471B2 (en) 2012-05-17 2016-04-19 Genetech, Inc. Process of making hydroxylated cyclopentapyrimidine compounds and salts thereof
CN104487430B (zh) 2012-05-17 2016-08-24 阵列生物制药公司 用于制造羟基化的环戊基嘧啶化合物的方法
TR201807444T4 (tr) 2012-05-17 2018-06-21 Genentech Inc Amino asit bileşiklerini hazırlama prosesi.
PE20150725A1 (es) 2012-05-17 2015-05-17 Genentech Inc Formas y formulaciones de un compuesto de pirimidinilciclopentano, composiciones y metodos de este
CN104470913B (zh) 2012-05-17 2018-07-20 阵列生物制药公司 用于制造羟基化的环戊基嘧啶化合物的方法
WO2014071194A2 (en) 2012-11-01 2014-05-08 Katz Robert S Methods for treating fibromyalgia
WO2014127350A1 (en) 2013-02-18 2014-08-21 The Scripps Research Institute Modulators of vasopressin receptors with therapeutic potential
US10131637B2 (en) 2013-03-15 2018-11-20 Shifa Biomedical Corporation Anti-PCSK9 compounds and methods for the treatment and/or prevention of cardiovascular diseases

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA200601426A1 (ru) * 2004-02-11 2007-02-27 Эмджен Инк. Производные пиримидина для использования в качестве лигандов ваниллоидных рецепторов и их применение для терапии боли
WO2008006040A1 (en) * 2006-07-06 2008-01-10 Array Biopharma Inc. Hydroxylated and methoxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
BASTIN R.J. ET AL., "Salt Selection and Optimisation for Pharmaceutical New Chemical Entities", ORGANIC PROCESS RESEARCH AND DEVELOPMENT, n. 4, no. 5, стр. 427-435, 2000. *
BASTIN R.J. ET AL., "Salt Selection and Optimisation for Pharmaceutical New Chemical Entities", ORGANIC PROCESS RESEARCH AND DEVELOPMENT, n. 4, no. 5, стр. 427-435, 2000. YU L, "AMORPHOUS PHARMACEUTICAL SOLIDS: PREPARATION, CHARACTERIZATION AND STABILIZATION", ADVANCED DRUG DELIVERY REVIEWS, т. 48, no. 1, стр. 27-42, 2001. HANCOCK B.C. ET AL., "CHARACTERISTICS AND SIGNIFICANCE OF THE AMORPHOUS STATE IN PHARMACEUTICAL SYSTEMS", JOURNAL OF PHARMACEUTICAL SCIENCES, т. 86, no. 1, стр.1-12, 1997. *
HANCOCK B.C. ET AL., "CHARACTERISTICS AND SIGNIFICANCE OF THE AMORPHOUS STATE IN PHARMACEUTICAL SYSTEMS", JOURNAL OF PHARMACEUTICAL SCIENCES, т. 86, no. 1, стр.1-12, 1997. *
YU L, "AMORPHOUS PHARMACEUTICAL SOLIDS: PREPARATION, CHARACTERIZATION AND STABILIZATION", ADVANCED DRUG DELIVERY REVIEWS, т. 48, no. 1, стр. 27-42, 2001. *

Also Published As

Publication number Publication date
CA2873663A1 (en) 2013-11-21
PH12014502538B1 (en) 2015-01-21
IL272037B (en) 2020-10-29
US9290458B2 (en) 2016-03-22
US9505725B2 (en) 2016-11-29
EP2858989A1 (en) 2015-04-15
KR20240066293A (ko) 2024-05-14
CR20140560A (es) 2015-01-12
KR20210095238A (ko) 2021-07-30
JP2018062536A (ja) 2018-04-19
WO2013173811A1 (en) 2013-11-21
AU2017279607C1 (en) 2019-05-16
CN104470912B (zh) 2017-11-14
AU2017279607B2 (en) 2018-11-22
JP2015517533A (ja) 2015-06-22
MX353041B (es) 2017-12-18
MA37650A1 (fr) 2016-11-30
IL272037A (en) 2020-02-27
AU2013262548A1 (en) 2015-01-15
AU2017279607A1 (en) 2018-01-18
HK1208462A1 (zh) 2016-03-04
MX2014013856A (es) 2015-02-18
HRP20200992T1 (hr) 2020-10-16
LT2858989T (lt) 2020-08-10
IL235712A0 (en) 2015-02-01
KR20220143143A (ko) 2022-10-24
ES2799512T3 (es) 2020-12-18
AU2013262548B2 (en) 2017-09-21
SG11201407618VA (en) 2015-01-29
IL235712B (en) 2020-01-30
CO7151489A2 (es) 2014-12-29
KR20200074252A (ko) 2020-06-24
US20160152575A1 (en) 2016-06-02
US20150274677A1 (en) 2015-10-01
CA2873663C (en) 2020-01-14
NZ702513A (en) 2016-09-30
EP3719014A1 (en) 2020-10-07
DK2858989T3 (da) 2020-06-02
CL2014003115A1 (es) 2015-07-03
PE20150725A1 (es) 2015-05-17
RS60417B9 (sr) 2021-07-30
SI2858989T1 (sl) 2020-08-31
PH12014502538A1 (en) 2015-01-21
RU2014151016A (ru) 2016-07-10
KR20150020200A (ko) 2015-02-25
PT2858989T (pt) 2020-06-25
BR112014028593A2 (pt) 2017-12-19
KR102125588B1 (ko) 2020-06-22
JP6518352B2 (ja) 2019-05-22
CN104470912A (zh) 2015-03-25
EP2858989B9 (en) 2021-04-14
EP2858989B1 (en) 2020-05-06
MY170086A (en) 2019-07-04
RS60417B1 (sr) 2020-07-31
PL2858989T3 (pl) 2020-11-16
HUE051254T2 (hu) 2021-03-01
JP6283663B2 (ja) 2018-02-21

Similar Documents

Publication Publication Date Title
RU2650511C2 (ru) Формы и составы пиримидинилциклопентанового соединения, композиции и способы, относящиеся к ним
US9162985B2 (en) Salts and solvates of a tetrahydroisoquinoline derivative
CN103221411B (zh) (R)-7-氯-N-(奎宁环-3-基)苯并[b]噻吩-2-甲酰胺盐酸盐单水合物的晶型
CN108884080B (zh) 激酶抑制剂化合物的多晶型、含其的药物组合物及其制备方法和应用
MX2013001533A (es) Forma cristalina de compuesto pirimido [6, 1-a] isoquinolin-4-ona.
EP3530271A1 (en) Crystalline form ii of dextral oxiracetam, preparation method therefor and use thereof
RU2627702C2 (ru) Кристаллические формы 1-(3-трет-бутил-1-п-толил-1н-пиразол-5-ил)-3-(5-фтор-2-(1-(2-гидроксиэтил)-1н-индазол-5-илокси)бензил) мочевины гидрохлорида
KR102678074B1 (ko) 무정형 형태의 akt 저해성 피리미디닐 - 사이클로펜탄 화합물, 조성물 및 이들의 방법
WO2023139313A1 (en) Novel sulfate salt forms of isochroman-imidazole structured alpha-2a adrenoceptor agonist
CN105814071A (zh) 类固醇样化合物的多晶型物及其制备和使用方法
CN112770731A (zh) 以4’-硫代核苷类化合物为活性成分的口服药物组合物、其制备方法及其用途
JP5589097B2 (ja) ダサチニブ多結晶体、並びにその調製方法及び薬物組成物